Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy.

Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy. Inflamm Bowel Dis. 2019 Aug 14;: Authors: Feagins LA, Kim J, Chandrakumaran A, Gandle C, Naik KH, Cipher DJ, Hou JK, Yao MD, Gaidos JKJ Abstract BACKGROUND: Patients with inflammatory bowel disease (IBD) may be at higher risk for complications from radiation treatment for prostate cancer. However, available data are limited, and controversy remains regarding the best treatment approach for IBD patients who develop prostate cancer. METHODS: A retrospective cohort study across 4…

Read More

The Incidence and Risk Factors of Pneumocystis jirovecii Pneumonia in Korean Patients with Inflammatory Bowel Disease.

The Incidence and Risk Factors of Pneumocystis jirovecii Pneumonia in Korean Patients with Inflammatory Bowel Disease. J Gastroenterol Hepatol. 2019 Aug 14;: Authors: Nam K, Park SH, Lee J, Jo S, Kim SO, Noh S, Park JC, Kim JY, Kim J, Ham NS, Oh EH, Song EM, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK Abstract BACKGROUND AND AIM: Little is known whether routine prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is needed in patients with inflammatory bowel disease (IBD) on immunosuppression, especially in Asian populations. We,…

Read More

Complications while waiting for IBD surgery- short report.

Related Articles Complications while waiting for IBD surgery- short report. J Crohns Colitis. 2019 Aug 12;: Authors: Wasmann KA, IBD study group Amsterdam UMC, location AMC Abstract BACKGROUND AND AIMS: While striving to meet the quality standards for oncological care, hospitals prioritize oncological procedures more frequently, resulting in longer waiting times to surgery for benign diseases like inflammatory bowel disease (IBD). The aim of this short-report is to highlight the potential consequences of a longer interval to surgery for IBD patients. METHODS: The mean waiting time to elective surgery for…

Read More

Genetic Variations at rs3129891 and rs77005575 are Associated With Reduced Expression of Enteric α-defensins in IBD Patients.

Related Articles Genetic Variations at rs3129891 and rs77005575 are Associated With Reduced Expression of Enteric α-defensins in IBD Patients. J Clin Gastroenterol. 2019 Aug 09;: Authors: Deng Q, Tan G, Deng F, Zhi F Abstract BACKGROUND AND AIMS: Human enteric antimicrobial peptides composed predominantly of human enteric α-defensins (HD5 and HD6) are important in the mucosal antimicrobial barrier. Previous studies have identified that genetic variations at rs2066844, rs2066845, rs2066847 are associated with diminished enteric α-defensins in ileal Crohn’s disease (CD). However, genetic variations associated with enteric antimicrobial peptides in colonic…

Read More

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.

Related Articles Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019 Aug 12;: Authors: Colombel JF, D’haens G, Lee WJ, Petersson J, Panaccione R Abstract BACKGROUND AND AIMS: Management of Crohn’s disease and ulcerative colitis has typically relied upon treatment intensification driven by symptoms alone. However, a ‘treat-to-target’ management approach may help to address underlying inflammation, minimise disease activity at early stages of inflammatory bowel disease, limit progression, and improve long-term outcomes. METHODS: A systematic literature review was conducted to…

Read More

Use of narrative concepts in the EHR to validate genetic determinants of treatment response in a virtual inflammatory bowel disease cohort.

Related Articles Use of narrative concepts in the EHR to validate genetic determinants of treatment response in a virtual inflammatory bowel disease cohort. Clin Gastroenterol Hepatol. 2019 Aug 09;: Authors: Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Savova G, Shaw SY, Churchill S, Burke KE, Karlson EW, Murphy SN, Kohane I, Liao KP, Xavier RJ PMID: 31404664 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31404664?dopt=Abstract

Read More

Acceptability, Tolerability and Safety of Faecal Microbiota Transplantation in patients with active Ulcerative Colitis (AT&S Study).

Acceptability, Tolerability and Safety of Faecal Microbiota Transplantation in patients with active Ulcerative Colitis (AT&S Study). J Gastroenterol Hepatol. 2019 Aug 13;: Authors: Sood A, Singh A, Mahajan R, Midha V, Mehta V, Gupta YK, Narang V, Kaur K Abstract BACKGROUND: Faecal microbiota transplantation (FMT) targets gut microbiome dysbiosis and is an emerging therapy for ulcerative colitis (UC). Though initial results with FMT in patients with active UC are encouraging, data regarding its acceptability, tolerability and safety are scant. METHODS: A retrospective analysis of patients with active UC (Mayo clinic…

Read More
<< Go Back